Research Papers:

Reduced E-cadherin facilitates renal cell carcinoma progression by WNT/β-catenin signaling activation

Xinqi Zhang, Mingxi Yang, Hua Shi, Jianxin Hu, Yuanlin Wang, Zhaolin Sun and Shuxiong Xu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:19566-19576. https://doi.org/10.18632/oncotarget.15361

Metrics: PDF 2502 views  |   HTML 2688 views  |   ?  


Xinqi Zhang1, Mingxi Yang2, Hua Shi2, Jianxin Hu2, Yuanlin Wang2, Zhaolin Sun2, Shuxiong Xu2

1Emergency Department, General Hospital of Jinan Military Area, Jinan, Shandong, 250031, China

2Department of Urology, Guizhou Provincial People’s Hospital Affiliated to Guizhou Medical University, Guiyang, Guizhou, 550002, China

Correspondence to:

Shuxiong Xu, email: [email protected]

Keywords: renal cell carcinoma, E-cadherin, β-catenin, immunohistochemistry (IHC)

Received: September 26, 2016     Accepted: January 16, 2017     Published: February 15, 2017


Reduced expression of E-cadherin was observed in renal cell carcinoma (RCC). However, its potential clinical value and correlation with WNT/β-catenin signaling in RCC progression was still unclear. Immunohistochemical staining was performed in RCC tissue microarray to examine the expression status and prognosis value of E-cadherin and β-catenin. The potential role of E-cadherin in β-catenin translocation was analyzed with immunobloting assays. A significant negative correlation was observed between E-cadherin and β-catenin expression in RCC tissues. E-cadherin inhibits β-catenin translocation from membrane to cytoplasm in RCC tissues, which was an important step for WNT/β-catenin signaling. Reduced E-cadherin expression was associated with poor prognosis. More importantly, E-cadherin-/β-catenin+ was an independent detrimental factor for survival estimation of RCC patients. Reduced E-cadherin expression in RCC promoted cancer progression via WNT/β-catenin signaling pathway activation. E-cadherin/β-catenin provides a valuable prognosis marker for RCC, which may be an effective target for RCC therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15361